Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed · Phase 2 · Has a placebo group

Conditions studied: Advanced or Metastatic Non-Small Cell Lung Cancer

In brief

This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.

Key facts

Study ID

NCT00716534

Run by

AbbVie (prior sponsor, Abbott)

People needed

145

Starts

2008-06-01

Expected to finish

2012-04-01

Last updated by the study team

2013-04-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must be at least 18 years of age.
• Subject must have cytologically or histologically confirmed non-squamous NSCLC
• Subject must have recurrent or advanced (Stage IIIb with pleural or pericardial effusion) or metastatic (Stage IV) disease that is not amenable to surgical resection or radiation with curative intent.
• Subject has measurable disease, defined as at least 1 unidimensional measurable lesion on a computed tomography (CT) scan as defined by RECIST (for subjects in the randomized portion only).
• Subject has an ECOG Performance Score of 0-1.
• Willing to take adequate measures to prevent pregnancy.

You may not qualify if…

• The subject has NSCLC with a predominant squamous cell histology
• Subject has hypersensitivity to paclitaxel.
• Subject has received any anti-cancer therapy for treatment of NSCLC.
• Subject has received radiation therapy within 21 days of Study Day 1.
• Subject has had major surgery within 21 days.
• Subject has untreated brain or meningeal metastases.
• Subject is receiving therapeutic anticoagulation therapy.
• Subject has a central thoracic tumor lesion as defined by location within the hilar structures.
• Subject has proteinuria CTC Grade > 1 at baseline.
• Subject has a history of, or currently exhibits clinically significant cancer related events of bleeding.
• The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (BP) > 90 mm Hg or systolic BP > 140 mm Hg.
• The subject has a history of myocardial infarction, stroke or Transient Ischemic Attack (TIA) within 6 months of Study Day 1.
• The subject has a documented left ventricular (LV) ejection fraction < 50%.
• The subject has known autoimmune disease with renal involvement (i.e., lupus).
• The subject is receiving combination anti-retroviral therapy for HIV.
• The subject has clinically significant uncontrolled condition(s).
• The subject has a history of another active cancer within the past 5 years.
• The subject has active ulcerative colitis, Crohn's disease, celiac disease or any other conditions that interfere with absorption.
• The subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.
• The subject is pregnant or breast feeding.

Where it is running

• Site Reference ID/Investigator# 15850 — Chandler, Arizona, United States
• Site Reference ID/Investigator# 15846 — Peoria, Arizona, United States
• Site Reference ID/Investigator# 15841 — Miami, Florida, United States
• Site Reference ID/Investigator# 7179 — Atlanta, Georgia, United States
• Site Reference ID/Investigator# 15851 — Lansing, Michigan, United States
• Site Reference ID/Investigator# 15844 — Lebanon, New Hampshire, United States
• Site Reference ID/Investigator# 22443 — Hackensack, New Jersey, United States
• Site Reference ID/Investigator# 15848 — Greensboro, North Carolina, United States
• Site Reference ID/Investigator# 22444 — Canton, Ohio, United States
• Site Reference ID/Investigator# 15847 — Cleveland, Ohio, United States
• Site Reference ID/Investigator# 26842 — Hershey, Pennsylvania, United States
• Site Reference ID/Investigator# 13101 — Philadelphia, Pennsylvania, United States
• Site Reference ID/Investigator# 24122 — Philadelphia, Pennsylvania, United States
• Site Reference ID/Investigator# 19042 — Bedford Park, Australia
• Site Reference ID/Investigator# 23682 — Cairns, Australia
• Site Reference ID/Investigator# 21862 — Lismore, Australia
• Site Reference ID/Investigator# 19043 — Woodville South, Australia
• Site Reference ID/Investigator# 17703 — Jaú, Brazil
• Site Reference ID/Investigator# 23522 — Porto Alegre, Brazil
• Site Reference ID/Investigator# 15601 — Porto Alegre, Brazil
• Site Reference ID/Investigator# 17704 — Rio de Janeiro, Brazil
• Site Reference ID/Investigator# 22684 — Santo André, Brazil
• Site Reference ID/Investigator# 17702 — São Paulo, Brazil
• Site Reference ID/Investigator# 23582 — São Paulo, Brazil
• Site Reference ID/Investigator# 18964 — Kyjov, Czechia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.